Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer

Clinical trial NCT00684294 · TERMINATED

Trial details

NCT number: NCT00684294
Sponsor: Mary Crowley Medical Research Center
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Carcinoma, Advanced Metastatic

Start date: 2008-05-27
Primary completion: 2009-05-01
Enrollment: 46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.